Clinical Takeaway
In this small pilot trial of 20 adults with diagnosed insomnia, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo, suggesting that this cannabinoid combination did not improve objective sleep in the short term. These findings highlight that patient-reported improvements in sleep with cannabinoids may not align with measurable changes in sleep architecture. Clinicians should counsel patients that current evidence does not firmly support oral cannabinoids as effective sleep aids for insomnia disorder.
#13 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
What This Study Teaches Us
A single dose of THC/CBD (10 mg THC plus 200 mg CBD) suppressed REM sleep by about 34 minutes and reduced total sleep time by about 25 minutes in people with insomnia, while subjective sleep quality remained unchanged. The drug altered sleep architecture on high-density EEG but did not impair next-day alertness or cognition at 9+ hours post-dose.
Why This Matters Clinically
Many patients use cannabis for sleep, but we have limited data on how it actually changes sleep stages and whether morning-after effects occur. This small pilot provides objective electrophysiology data showing that cannabinoids do more than simply make people drowsy, they reshape sleep in ways that deserve clinical attention and further study before routinely recommending them as sleep aids.
Study Snapshot
| Study Design | Pilot randomized controlled trial, apparently single-dose crossover design |
| Population | 20 adults with DSM-5 insomnia disorder (16 female), mean age 46 years |
| Intervention | Single oral dose of 10 mg THC plus 200 mg CBD versus placebo |
| Primary Outcome | Sleep architecture and next-day alertness measured by 256-channel high-density EEG and objective cognitive/driving tests |
| Key Result | THC/CBD decreased total sleep time by 24.5 minutes and REM sleep by 33.9 minutes; no impairment on objective next-day measures, but small increase in self-reported sleepiness |
Where This Paper Deserves Skepticism
This is a very small pilot (N=20) with a single dose in a controlled lab setting, which limits generalizability to real-world chronic use or different cannabinoid ratios. The abstract does not clearly specify whether this was truly blinded or crossover design, and nine hours post-dosing may not capture sustained next-day impairment in driving or cognition for all individuals. The 200 mg CBD dose is unusually high and not reflective of typical cannabis products, and we don’t know whether the REM suppression persists with repeated dosing or whether tolerance develops.
Dr. Caplan’s Take
I find this study methodologically sound in its use of high-density EEG to characterize sleep architecture, which goes beyond most cannabis-sleep literature. What concerns me is that REM suppression of this magnitude, even without acute next-day cognitive deficits, raises questions about longer-term effects on memory consolidation and emotional regulation that this pilot cannot answer. The discrepancy between objective sleep quality findings and reduced REM sleep suggests we’re modifying sleep without necessarily improving it in ways patients experience or need. Until we see data on chronic use and on outcomes that matter to insomniacs like daytime function over weeks, I counsel patients that cannabinoids reshape sleep in ways we don’t yet understand clinically.
Clinical Bottom Line
Oral THC/CBD suppresses REM sleep acutely without apparent next-day cognitive or driving impairment at 9 hours, but this pilot offers no evidence that it improves sleep quality or insomnia outcomes. Larger, longer-term trials are needed before recommending cannabinoids as a standard sleep aid.
| |
Have thoughts on this? Share it:
